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Abstract
A gene therapeutic approach to treat osteoarthritis (OA) appears to be on the horizon for millions 
of people who suffer from this disease. Previously we described optimization of a scAAVIL-1ra 
gene therapeutic vector and initially tested this in an equine model verifying long-term 
intrasynovial IL-1ra protein at therapeutic levels. Using this vector, we carried out a dosing trial in 
six horses to verify protein levels and establish a dose that would express relevant levels of 
therapeutic protein for extended periods of time (8 months). A novel arthroscopic procedure used 
to detect green fluorescence protein (GFP) fluorescence intrasynovially confirmed successful 
transduction of the scAAVGFP vector in both the synovial and cartilage tissues. No evidence of 
intra-articular toxicity was detected. Immune responses to vector revealed development of 
neutralizing antibodies (Nabs) within 2 weeks of administration, which persisted for the duration 
of the study but did not lower protein expression intra-articularly. Re-dosing with a different 
serotype to attain therapeutic levels of protein confirmed establishment of successful transduction. 
This is the first study in an equine model to establish a dosing/redosing protocol, as well as 
examine the Nab response to capsid and supports further clinical investigation to determine the 
clinical efficacy of scAAVIL-1ra to treat OA.
INTRODUCTION
Osteoarthritis (OA) continues to plague both the aging as well as active younger generations 
around the world. Current drug therapies that exist have mainly symptom-modifying effects 
and consist of analgesics, nonsteroidal anti-inflammatory drugs, glucosamine and 
chondroitin sulfate, and intra-articular injections of corticosteroids or hyaluronan.1,2 
Disease-modifying effects of corticosteroids and/or corticosteroids combined with 
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hyaluronan have been reported in animal studies,3,4 but in humans the efficacy remains 
controversial as this treatment is known to be short-acting, prone to potential detrimental 
cartilage changes and has questionable effects on modifying the course of OA.5,6
One specific disease-modifying drug that has shown promise is interleukin receptor 
antagonist protein (IL-1ra).7–10 IL-1ra is a naturally occurring inhibitor, which, through its 
binding ability to the IL-1β receptor, inhibits the catabolic cytokine IL-1β.11 IL-1β is 
considered to be one of the most important pro-inflammatory cytokines in inflamed joints.12 
A myriad of publications have revealed significant correlations of increased levels of IL-1β 
with biochemical and histologic evidence of OA.12–17 There have also been incremental 
increases of the IL-1ra/IL-β ratios associated with escalating grades of OA.15 Chondrocytes 
are the major cellular targets of IL-1β and have been found to have more receptors for IL-1β 
in sites of osteoarthritic cartilage compared with OA cartilage.12 There continues to be 
mounting clinical evidence that proves efficacy of products containing high levels of IL-1ra 
especially in the high motion joints that have the highest occurrence of OA such as the hip 
and the knee.9,10,18
Gene delivery of various therapeutic genes for arthritis is now well-established.19,20 Adeno-
associated virus (AAV) has repeatedly been found to deliver long-term protein production 
with minimal detrimental effects to the joint tissues compared with the other viral vectors.21 
Early studies utilized single stranded AAV with good success; however, with the 
development of self complementary AAV (scAAV), higher levels of protein could be 
produced more quickly (1 week with double stranded compared with 3–4 weeks with single 
stranded) suggesting that this vector is the preferred choice with respect to gene therapy 
trials.22
Although proof-of-principle was established for arthritis gene therapy using retro and 
adenoviral vectors to deliver anti-catabolic and anabolic vectors to treat OA, we and others 
pursued more efficient, enhanced production through testing of various AAV (2 and 2.5) 
serotypes both in vitro and in vivo, which revealed superior efficiency.22–26 Further, specific 
genetic alterations of the therapeutic transgene such as codon optimization as well as testing 
various promoters in joint tissues, revealed that the scAAVoptimizedequineIL-1ra vector 
produced significant and therapeutic protein production within the middle carpal and 
metacarpophalangeal joints of horses.24 Horses have now been used for decades as animal 
models to mimic osteoarthritic conditions of human joint disease and are considered a highly 
relevant animal model due to the size of their joints, the thickness of their cartilage and the 
character of their subchondral bone.27,28 Thus, we further pursued a scAAVIL-1ra dosing 
protocol to determine proper dosing of vector genomes to be injected into joints that have 
similar size and synovial volumes to the human knee. Proper dosing of scAAVIL-1ra is 
important as the efficacy of IL-1ra gene therapy is determined by levels of the protein in 
relation to levels of IL-1β.15 Conversely, the cost of vector can be prohibitive to realistic 
expectations of instituting this therapy in clinical patients. Further, we sought to determine 
whether intra-articular tissues within our horses maintained tissue transduction and protein 
expression by using a green fluorescence protein (GFP) encoding transgene to track protein 
production for up to 240 days post injection.
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It has also been well-established that neutralizing antibodies (Nabs) are produced in 
response to AAV-mediated gene transfer.29–33 The role of Nabs is important both to 
establish the effects from a single intra-articular injection as well as the ability to re-inject 
either the same serotype vector or perhaps another serotype to ‘augment’ diminishing levels 
or levels that never reached therapeutic efficacy. Our objectives of this study were four fold: 
(1) establishment of vector dose of scAAV2equineoptIL-1ra in an equine joint that will 
produce therapeutic levels of protein (10–400 ng ml−1); (2) determination of longevity and 
location of protein expression following one injection of an optimal dose; (3) determine the 
NAb response to the dose administered and; (4) assess whether re-injection of an alternative 
serotype of AAV would result in augmented production of therapeutic levels of the IL-1ra 
protein in the presence of nAb levels persisting for the length of the study. Our hypotheses 
based on our preliminary horse study were: (1) one of the three doses tested would result in 
sustained therapeutic levels (10–400 ng ml−1) of protein for the duration of study (8 
months); (2) the location of protein production would be only within the target tissue and 
most prevalent in chondrocytes verses synoviocytes as tracked using a GFP marker gene and 
a novel in situ arthroscopic imaging system; (3) the Nab response would occur following 
injection of three different doses and (4) if Nab responses persisted, injection of an 
alternative serotype would result in a ‘rebound’ of therapeutic protein production.
RESULTS
Intra-articular measurement of IL-1ra levels according to dose and time
Six mature horses were dosed in the middle carpal space with scAAVIL-1ra, scAAV2GFP or 
saline (Figure 1). Enzyme-linked immunosorbent assay (ELISA) measurement of intra-
articular protein levels revealed minimal to no IL-1ra at baseline (Day 0) for all horses 
(Figure 2). Fourteen days following injection, which was also the first day of synovial fluid 
collection, high (5 × 1012) dosed joints revealed a robust increase in IL-1ra levels of 537ng 
ml−1 (±195 ng ml−1 = s.d. between joints). The level of IL-1ra protein fluctuated but 
consistently remained between an average of 200 and 550 ng ml −1 for 98 days in the joints 
receiving the highest dose. Past 168 days, levels of IL-1ra gradually decreased over time but 
remained detectable for the duration of the study (D276). Middle dosed horses (5 × 1011) 
had an average of between 100 and 300 ng ml −1, an average 1.5-fold lower amount of 
IL-1ra concentrations in the synovial fluid than the high dosed horses. These horses were 
euthanized at Day 98. Low (5 × 1010) dosed horses had 10–80 ng ml −1 levels of IL-1ra in 
the synovial fluid, which was an average of 2.9-fold lower amount than levels of IL-1ra of 
the middle dosed horses. Levels of IL-1ra for the lowest dosed horses were barely detectable 
at Day 154, the date chosen just before redosing occurred. Re-dosing was carried out only in 
the low dosed horses in these studies to mimic the clinical scenario of inadequate amounts of 
protein produced from the first vector injection and the need to elevate those levels.
Contralateral joints (joints injected with saline or AAVGFP) in the high dosed horses had a 
mild increase in IL-1ra 28 days following injection and increased to an average of 38 ng 
ml −1 at day 70 and dropped to barely detectable at day 126 as described previously.24 
Contralateral joints in horses receiving the middle or the low dose scAAV2IL-1ra had barely 
detectable levels of IL-1ra.
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Synovial fluid white blood cell (WBC) counts and total protein (TP) levels ranged between 
0.5 and 2 cells per ml and 1.5 and 3.5 g dl −1, respectively, for all joints close to the range of 
normal (0.5–2 g dl −1) (Figure 2). There were minimal differences in synovial fluid WBC 
counts (pre 2–3 g dl −1 and post 1–2 g dl −1) and TP between scAAV2IL-1ra injected joints 
and saline injected joints. An unexplained high data point was observed in one dosed horse 
at Day 112 in which the WBC count was 3.8–4 cells per ml.
IL-1ra redosing in low dose joints
We sought to investigate whether synovial joints that were producing minimal to no IL-1ra 
protein due to a low dose administration would produce augmented levels of IL-1ra 
following a re-injection of the high dose (5 × 1012) alternative serotype (scAAV6 IL-1ra, 
Figure 3). Two weeks following Day 154, a robust increase of IL-1ra was detected by 
ELISA in two animals. One horse expressed very high levels of IL-1ra (pre 0 ng ml −1 and 
post 230–1000 ng ml −1) for over 100 days with a gradual decline in IL-ra at 273 days. 
Unexpectedly, low dosed horse #2 yielded initial levels identical to redosed horse #1 with 
700 ng ml−1 at 2 weeks post injection followed by rapid diminution at 4 weeks post injection 
(suggestive of immune response or vector silencing yet to be determined). The WBC counts 
and TP for re-injected joints remained within normal range during this time and did not 
differ significantly from the contralateral joints injected with saline or scAAV6GFP.
No lameness or pain on flexion of injected joints was noted and no increase in joint 
circumference was observed during the study in response to injections of scAAV2IL-1ra or 
scAAV6IL-1ra (re-injected joints), scAAV2GFP or saline in all test animals.
Intra-articular GFP fluorescence and intra-articular histology
Cartilage and synovial biopsies were taken from joints injected with scAAVGFP and 
examined under fluorescent microscopy to determine the level of tissue transduction in 
specific cell types (Figure 4). High and low dosed horses had cartilage and synovium 
removed at Day 276 and middle dosed horses had tissue harvested at Day 98 as previously 
described. Cartilage from the high (Figure 4b) and middle (Figure 4d) dosed horses revealed 
fluorescent chondrocytes at the time of harvest (Day 276 for high dosed horses and Day 98 
for middle dosed horses) consistent with cell type transduction identified in a previous 
study24 and consistent with IL-1ra levels within this study. Cartilage from lowest dosed 
horses (Figure 4f) did not reveal fluorescent chondrocytes in the cartilage following injection 
with scAAV2GFP when analyzed at Day 276. Synovium did not reveal fluorescence from 
any horses injected with scAAV2GFP past Day 98 consistent with expected natural turnover 
of these cells.34 Arthroscopic images of the joints injected with scAAV6GFP (the 
antebrachiocarpal joint of re-injected horses) revealed fluorescent chondrocytes when 
viewed arthroscopically 122 days following GFP injection (Figure 4i and j and 
Supplementary Video 1 and 2).
Histology (hematoxilin and eosin (H&E) and Toluidine Blue) of cartilage and H&E of 
synovium did not reveal any inflammation in response to vector injection. There were no 
pathologic changes noted in any of the tissues from either the saline, scAAVGFP or 
scAAVIL-1ra.
Goodrich et al. Page 4













Vector distribution and joint histology
Viral distribution of IL-1ra viral genomes was tested by quantitative PCR analysis on an 
extensive panel of tissues harvested for all test animals (Figure 5). The vector genome levels 
in all nonjoint tissues were consistent with what was observed in our previous study (below 
1.5 vector genomes (vg per cell).24 Viral distribution of these genomes was also examined in 
the capsule, cartilage, pericapsule and synovium for high, middle and low dosed joints 
injected with scAAV2IL-1ra as well as the control (saline) injected joints (data not shown). 
Inconsistent with our previous study, we were unable to detect vector genomes in joint 
tissues from joints injected with scAAV2IL-1ra or scAAV6IL-1ra at these extended time 
points, suggesting variability in tissue sampling as supported by our observed GFP 
transduction. This may indicate a need to adapt this protocol to conduct a broader sampling 
of entire organs to capture truly representative genome copy numbers per cell.
Presence of Nabs
In an attempt to determine the presence and levels of Nabs that developed to injected vector 
capsid, we measured levels of Nabs in the serum of all horses over the entire course of these 
studies. Data for the high and low dosed horses are shown in Figure 6. Figures 6a and b 
(high dosed horses) reveal that Nabs to serotype 2 at levels between 1:5 to 1:50 were present 
at Day 14 (the first time point examined following injection) and remained above 1:5 in both 
high dosed horses until the end of the study (Day 276). Nabs were also detected to the 
alternative capsid (AAV6) in the high dosed horses that only received AAV2 injections 
(Figures 6a and b). In both of the high dosed horses, Nabs to serotype 6 (note that AAV6 
was not injected in these horses) were between 0 and 1:10 000 up until Day 182 when 
interestingly the levels of IL-1ra decreased to levels <20 ng ml −1. As seen in mice these 
cross-reactive Nabs to serotype 6 were either not detected or were below clinical 
significance until the end of the study.30 For lower dosed/redosed horses (Figure 6c and d) 
Nabs to S2 remained fairly low (0–1:50) until those horses were redosed with scAAV6IL-1ra 
at which time Nab’s to serotype 2 were between 1:50 and 1:10,000. When redosing with 
AAV6, similarly the Nabs to serotype 6 also rose from 0 to between 1:50 and 1:10,000 for 
the duration of the study. From the responses of Nabs to vector injection it appears responses 
are dose and vector dependent.
DISCUSSION
The majority of dosing studies for gene therapeutic approaches are done in laboratory 
animals or species that do not mimic the size or architecture of the human joint.22,35,36 The 
equine joint has been found to be most closely associated with the human joint in terms of 
cartilage and subchondral bone thickness, joint architecture and synovial fluid volume.27,37 
While the use of the horse for dosing studies is expensive, the translational value of 
performing this study should provide valuable data to the human arena to suggest 
appropriate dosing for similarly sized joints using scAAVIL-1ra. We based our escalating 
vector dosage on previous work by us24 and others21,31 who established therapeutic levels of 
various AAV transgenes in joints similar in size to the human knee. The horse has been used 
extensively as a translational model to humans for OA37,38 and cartilage repair39,40 and we 
believe this dosing study is suggestive of levels that can be expected in a similarly sized 
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human knee. The animal numbers and samples obtained in this study are informative albeit 
somewhat restricted based on expense of using the horse as a model verses rats, mice or 
rabbits.
We attempted to deliver clinical doses that would be relevant and translational directly to 
human joints based on previous studies demonstrating prolonged expression of therapeutic 
expression of IL-1ra transgene.24 The highest vector dose administered in the present study 
was 5 × 1012 vg and resulted in IL-1ra levels between 80 ng ml−1 and 750 ng ml−1 for up to 
168 days and thereafter levels between 10 and 60 ng ml−1 to the end of the study. Doses of 
either recombinant (Anakrina) or endogenous IL-1ra (autologous conditioned serum) 
administered to humans with OA, juvenile OA or rheumatoid arthritis or horses with OA 
either systemically (anakrina) or intra-articularly (anakrina or autologous conditioned 
serum) have resulted in broad ranges of intra-articular levels of IL-1ra between 30 pg ml−1 
and up to 30 000 pg ml−1.41,42 Levels depending on the length of time synovial fluids were 
taken following treatment and types of ELISA used to measure levels.
The levels of IL-1ra postulated to effectively antagonize IL-1β binding to the IL-1 receptors 
range from 10 fold to 1000 fold that of IL-β.11,43–46 Therefore effective levels of IL-1ra 
within the joint would depend on how much IL-1β is present as a result of the inflammatory 
process intra-articularly. In patients with joint inflammation, levels of IL-1β have been 
reported to be anywhere between 1 pg ml−1 and up to 600 pg ml −1.10,42 Therefore levels of 
synovial IL-1ra theoretically would ideally range from 10 to 6000 pg ml −1. Levels in this 
study far surpass this range; however, it is unknown ‘how much is enough’ and to our 
knowledge there are no detrimental effects associated with high levels of IL-1ra in the joint.
The drawback of direct injection of recombinant or endogenous IL-1ra is quickly 
diminishing levels of protein intra-articularly and even slow release formulations have only 
mildly prolonged levels of IL-1ra.43,47,48 The need for sustained levels of IL-1ra to protect 
cartilage degeneration has been highlighted by Rutgers et al.49 in which levels of 
proteoglycans within osteoarthritic cartilage were not ‘rescued’ by autologous conditioned 
serum largely due to the short half-life of the protein. A gene therapeutic approach to 
enhancing intra-articular IL-1ra levels circumvents the rapid decline of IL-1ra levels when 
administered using recombinant or endogenous IL-1ra harvested from autologous 
conditioned serum. Several gene therapeutic studies have revealed that IL-1ra gene therapy 
results in enhanced levels of intra-articular IL-1ra for sustained periods of time and provides 
efficacy in reducing inflammatory cytokines in induced arthritis.22,38,50–52 Further, IL-1ra 
gene therapy in small pilot studies performed in human joints has resulted in elevated levels 
of IL-1ra and a reduction of IL- β and pain.53,54 This has resulted in an intense effort within 
the gene therapy community to bring this approach to fruition as a potential effective 
treatment for OA.19
As AAV gene delivery to joints continues to show promise in animals24,31,52 and 
people,21,55 questions have surfaced as to whether immunity to AAV vectors would result in 
an inability to re-dose patients with AAV vectors that had an inadequate rise of protein to 
therapeutic levels. The inability to utilize AAV gene therapy following previous exposure to 
AAV has been well-established.56 To address these concerns, we injected all horses with 
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AAV2 and then redosed the two lowest dosed horses (5 × 1010 vg) with AAV6 at the highest 
dose (5 × 1012 vg) (Figure 3) to determine if an alternative serotype could result in enhanced 
IL-1ra bypassing any Nabs to AAV2. Only the low dosed horses were redosed to mimic the 
clinical scenario of minimal levels of IL-1ra and the subsequent need to re-dose to result in 
therapeutic levels of IL-1ra. In both horses, we were able to induce high levels of IL-1ra 
intra-articularly following injection of scAAV6-IL-1ra into the same joints. In one horse, 
levels stayed high for the duration of the study and in the other horse levels were not 
sustained. It is unknown if the latter horse’s immune system recognized and blocked the 
IL-1ra or if levels dropped due to a less effective transduction of AAV6. Experiments are 
underway to clarify this. Regardless, these results are promising in that they suggest that the 
ability to re-dose a patient with an alternative serotype is a realistic option.
We also measured Nab’s to AAV2 and AAV6 throughout the duration of the study (Figure 6) 
to determine the level of immune stimulation to each serotype. Results suggested that AAV2 
injected at the dosage of 5 × 1012 vg resulted in stimulation of Nabs to both AAV2 and 
AAV6. Horses injected with low dose AAV2 (5 × 1010) had Nabs to AAV2 but at a lower 
level than the horses injected with the high (5 × 1012) dose and Nabs to AAV6 were very low 
(between zero to 1:50). On redosing with AAV6IL-1ra, Nabs to AAV6 rose and remained 
high until the duration of the study affirming the potential to re-dose patients with alternative 
AAV serotypes if therapeutic levels are not reached with the initial dose. We used serum to 
measure Nabs as this is an accurate determination of inhibition of AAV within the syovial 
fluid as shown in previous studies.32,33 The Nab levels determined from this study 
demonstrate that once a particular AAV serotype is utilized to result in therapeutic levels of 
protein intra-articularly, Nabs stimulated from the original injection to that serotype rise to 
levels that in previous studies negate any redosing with the original serotype used.32,33
To determine the level of tissue transduction on a qualitative basis, we developed further a 
novel, in situ analyzation of tissues transduced by AAVGFP first described in a previous 
study by our group.24 This system combined with fluorescent microscopy of cartilage 
explants (Figure 4) revealed the superficial layer of chondrocytes in cartilage that were 
efficiently transduced with AAVGFP. Figures 4i and j reveal the arthroscopic confirmation 
that AAVGFP transduced cells are present throughout the cartilage surface and to the edges 
of the cartilage of the carpal bones. Supplementary Videos (S1 and S2) also reveals this 
throughout the joint examined arthroscopically. Synovial tissue did not reveal fluorescence 
when the joints were arthroscopically examined and then subsequently observed under 
fluorescent microscopy. As confirmed in other intra-articular gene therapy studies, synovial 
cells within the synovial tissue and chondrocytes within the cartilage are the principle 
targeted cells for initial injection; however, synovial turnover results in most transduced cells 
within the synovium to be absent (due to turnover) between 4 and 6 weeks following 
injection leaving the chondrocytes as the stable, long-term protein producing cells.24,34 
Although initial gene therapy studies in laboratory animals suggested that cartilage is not 
successfully transduced, this and other work in the horse has shown long-term expression of 
AAV in this enduring population of quiescent and minimally dividing cell population19,24,31 
and therefore highlight the potential for human cartilage to also result in sustained levels of 
protein production given its similarities to the horse.27,37 GFP expression persisting in 
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chondrocytes rules out the possibility of immune response to GFP as a primary reason of 
loss of transgene expression in synoviocytes.
Biodistribution studies revealed negligible levels of vector genome within the peripheral 
organs collected for vector detection consistent with our previous study in which no 
significant levels of vector genomes were detected after assaying two horses 23 and 182 
days following scAAVIL-1ra intra-articular injection.24 It also highlights the safety of AAV 
intra-articular gene therapy and the localization of this vector within the joint.
There are currently many studies reporting efficacy of various retro, lenti and adenoviral 
vectors for intra-articular gene therapy specifically to deliver IL-1ra for arthritis.22,24,38,57,58 
While these studies have provided proof-of-principle, gene therapy using an AAV-delivered 
IL-1ra transgene appears to provide the most stable transduction and results in the shortest 
time to protein production following in vivo injection. Further, it is associated with the least 
amount of intra-articular joint inflammation.24,52,56 While efficacy of IL-1ra protein level 
elevation is shown in this study in normal horses, it is important to determine the proper 
dose of scAAVIL-1ra that results in levels of IL-1ra that will be efficacious in antagonizing 
the effects of IL-1β in an equine model of OA.
SUMMARY
To our knowledge, this is the first dosing study to report levels of AAVIL-1ra according to 
vector amounts injected. Further, it is the first study to reveal the ability to re-dose a joint 
with an alternative serotype that results in high levels of therapeutic protein in a large animal 
model that for all intents and purposes mimics the human knee. Our hypotheses were proven 
in that: (1) the dose of 5 × 1012 appears to result in therapeutic levels of IL-1ra for at least 8 
months following injection; (2) the chondrocytes appear to be the stable, transduced cell 
population within the joint; (3) Nabs rise in response to various serotypes injected intra-
articularly; and (4) joints can be redosed with an alternative serotype of AAV and result in 
high therapeutic levels of protein. Further, the dose of 5 × 1012 appears to be safe and cause 
minimal to no detrimental effects in joints that are similar in size to the human knee. While 
the joints of horses in this study were normal, levels of IL-1ra may change due to 
inflammation since some promoters such as CMV may enhance protein production in an 
inflammatory environment. With the knowledge of the appropriate dose of scAAVIL-1ra that 
will result in therapeutic and long-term levels of IL-1ra production, a study to determine the 
efficacy of this gene therapeutic approach can begin.
MATERIALS AND METHODS
Clinical trial
All animal work was approved by Colorado State University IUCAC. Six skeletally mature 
horses between 2 and 5 years of age were dosed in the middle carpal joint with 
scAAVIL-1ra, scAAV2GFP vectors (both vectors having a CMV promoter and a polyA tail) 
or saline. All vectors used in the study were produced by the University of North Carolina 
vector core facility. Two horses were given 5 × 1012 vg, two were given 5 × 1011 vg and two 
were given 5 × 1010 vg, corresponding to high, middle or low doses, respectively. Three 
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animals received either scAAV2GFP or scAAV2IL-1ra in the left and right middle carpal 
joint, while the remaining three animals received either saline or scAAV2IL-1ra. At Day 
154, animals initially receiving the lowest dose of virus 5 × 1010 vg were given a second 
injection of either scAAV6IL-1ra or scAAV6GFP of 5 × 1012 vg in both carpal joints. 
Injections were administered into the upper (antebrachiocarpal) carpal space (scAAV6GFP 
only) or middle carpal space based on the location of the first injection. Physical 
examinations (lameness evaluation, pain on flexion and joint circumference) were performed 
at Day 0 and weekly for the duration of the study. Serum and synovial fluid samples were 
collected at Day 0 to establish baseline levels. Serum and synovial fluid samples were 
subsequently collected 2 weeks post injection and every other week thereafter for 39 weeks, 
at which time the animals were killed and tissue samples were collected for histology, 
biodistribution and functional assays.
Arthroscopic examination
Arthroscopic assessments were performed on both carpal joints of the horses given 
scAAV2GFP 1 month following administration of the viral constructs. Fluorescent filters on 
the arthroscope were used to evaluate synovial membrane and fibrous joint capsule and 
cartilage for fluorescing cells. Since one carpal joint had scAAV2GFP injected and the 
contralateral joint had scAAV2IL-1ra injected, the joints acted as a positive and negative 
control (for fluorescence), respectively. Fluorescence was imaged and video recorded.
Serum and synovial fluid evaluation and viral biodistribution
Serum samples were evaluated for circulating levels of IL-1ra with a commercially available 
equine IL-1ra ELISA (R&D Systems, Minneapolis, MN, USA). Synovial fluid samples were 
evaluated for TP and fluid cytology, as well as IL-1ra with the same previously mentioned 
ELISA kit. Serum samples were non-diluted and synovial fluid samples were diluted 1:40 in 
reagent diluent (1% bovine serum albumin in phosphate buffered saline) prior to IL-1ra 
evaluation. Samples were evaluated as per manufacturer’s instructions.
Serum samples from each horse at Day 0, Day 14, Day 70 and Day 154–276 were analyzed 
for the presence of Nabs against viral serotypes, specifically serotypes 2, 2.5, 3, 5 and 6. 
Two-ninety-three cells were plated to 50% confluency and allowed to equilibrate for 48 h at 
37 °C with 5% CO2. Serum samples from the time points listed above were diluted 1:2, 1:5, 
1:50, 1:500, 1:5000 and 1:10 000 in non-supplemented Dulbecco’s Modified Eagle’s 
medium, and added v/v (125 μl/125 μl) to scAAVGFP viral constructs to form a neutralized 
complex. These complexes were incubated at 37 °C as described above for 1 h, and were 
added to the 293 cells for 1 h. Neutralized complexes were removed from the 293 cells, and 
supplemented media (10% fetal bovine serum, 10 000 U penicillin/streptomycin/
amphotericinB, 1 N HEPES) for an additional 24 h. Cells were removed from plates with 
Accumax (Sigma-Aldrich, St Louis, MO, USA) and suspended in 0.1% bovine serum 
albumin/phosphate buffered saline for flow cytometry analysis.
The biodistribution of IL-1ra viral particles was investigated through collecting tissues from 
each animal and performing quantitative PCR for vector genome biodistribution studies. 
Tissue DNA was purified and the abundance of target DNA vector and reference sequences 
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was quantified as described.59 Data is reported as the number of double-stranded IL-1ra 
vector DNA molecules per two copies of the equine GAPDH locus, or in other words the 
number of vector DNA copies per diploid equine genome. The equine GAPDH primers are 
as follows: forward 5′-GATTGT CAGCAATGCCTCCT-3′; reverse 5′-
TGCCAAAGTGGTCATGGAT-3′. The IL-1ra primers are as follows: forward 5′-
AGCTTCCCGGCAACAATTA-3′; reverse 5′-GCAGAAGTGGTCCTGCAACT-3′.
Histology and explant evaluation
Tissue samples taken from the forelimb middle carpal joints from each horse were visualized 
with a fluorescent microscope. Images were captured using × 100 magnification, utilizing a 
fluorescein isothiocyanate fluorescent filter cube with an excitation of 495 nm and emission 
of 521 nm. Synovium, osteochondral sections, joint capsules and joint pericapsular tissues 
were placed in formalin. Osteochondral samples were removed from formalin within 72 h 
and decalcified using an EDTA-based decalcification solution. All samples were paraffin 
embedded and mounted onto charged slides. Tissues were deparaffinized and stained with 
hematoxylin and eosin, and osteochondral samples were also stained with Toluidine Blue. 
Briefly, samples were hydrated with a series of ethanol incubations; followed by 
hematoxylin stain, blue buffer solution and eosin counterstaining. Slides were rinsed with 
distilled H2O between each stain. Subchondral bone was deparaffinized and hydrated as 
described, and were incubated in 1% Toluidine Blue solution. Slides were rinsed between 
stains as described above, dehydrated and cover slipped for analysis. Histological sections 
were observed and scored for villous architecture, subintimal fibrosis, intimal hyperplasia, 
vascularity and inflammatory cell infiltration (synovium), and perilesional cloning, 
subchondral bone attachment, Toluidine staining, surface fibrillation and tidemark (articular 
cartilage), as previously described.24
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Middle carpal joints were injected with saline, scAAV2GFP, scAAV6GFP, scAAV2IL-1ra 
and/or scAAV6IL-1ra as illustrated in panels a–c. Panel a represents the high dosed horses 
and the dosage of vector (or saline) and joint injected. Panel b represents the middle dosed 
horses and the dosage of vector (or saline) and joint injected. Panel c represents the low 
dosed horses and the dosage of vector (or saline) and joint injected. The red-bordered text 
represents what was injected on Day 154. The right antebrachiocarpal (verses the middle 
carpal) joint was injected with scAAV6GFP so that transduction could be determined from 
that particular vector and not be confused with previous GFP transduction from middle 
carpal joint injection. Panel d represents the time at which animals were dosed and/or 
redosed (red border), arthroscopically assessed and euthanized. Synovial fluid samples were 
collected for analysis at each time point listed.
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(a–f) Mean IL-1ra (ng ml−1) (left axis), total protein (g dl−1) and WBC (cells per μl) (right 
axis) levels in high dosed, middle dosed, low dosed and contralateral control limb synovial 
fluid samples (n =2). S.d. is shown for IL-1ra levels only. Time frames differ (x-axis) 
because the middle dosed animals were euthanized at Day 98 and the low dosed animals 
were given a second administration of virus at Day 154 (therefore x-axis extends up until the 
last time point before the second injection). High dosed joints produced an average between 
200 and 550 ng ml−1 up to day 98 and then between 20 and 200 ng ml−1 thereafter. Middle 
dosed joints produced between an average of 100 and 300 ng ml−1 up to day 98, at which 
time those horses were terminated, and low dosed joints produced 10–80 ng ml−1 up to day 
140, at which point they were redosed (x-axis only goes to last time point before re-
injection). WBC and TP were not different between joints injected with scAAV2IL-1ra or 
scAAV2GFP or saline.
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(a–d) IL-1ra (ng ml−1), total protein (g dl−1) and WBC (cells per μl) levels in low dosed and 
contralateral control limb synovial fluid samples after the second administration of virus. 
The x-axis begins at Day 154 when re-injection took place. One horse (a) whose joint was 
re-injected (scAAV6IL-1ra) had IL-1ra level rise to 675 ng ml−1 and quickly drop while the 
other horse (c) that was re-injected (also with scAAV6IL-1ra) rose to a high level of 1190 ng 
ml−1 and remained elevated until Day 273. WBC and TP were not different between any 
injected joints.
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(a–j) Microscopic imaging of cartilage explants 48 h after euthanasia and collection. 
Explants were observed under × 100 magnification with (right image) and without (left 
image) a fluorescent filter (excitation of 495 nm, emission of 521 nm). High dosed 
(scAAV2GFP) joints are shown in panels a and b, middle dosed joints are shown in c and d, 
and low dosed joints are shown in panels e and f. Cartilage from the joints re-injected with 
scAAV6GFP are shown in panels g and h. Panels i and j represent arthroscopic images 4 
months following a joint injected with scAAVGFP. The bright green dots represent 
transduced chondrocytes within the cartilage viewed arthroscopically following injection.
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Panels a–e represents the biodistribution of IL-1ra vector genomes per cell (vg per cell) in 
all tissues collected at the termination of the study. Standard errors are shown (n =6). Levels 
of vector genomes >1 vg per cell are considered significant. No samples were >0.8 vg per 
cell.
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(a–d) Serum neutralizing antibody titers against scAAV2IL-1ra and scAAV6IL-1ra in high 
(a and b) and low (c and d) dosed animals. Levels of neutralizing antibodies to S2 are 
highest in the high dosed horses (a and b) and are low for most of the length of the study to 
S6. Levels of neutralizing antibodies to S2 are also high in the low dosed horses (c and d). 
Neutralizing antibodies to S6 rise following injection at Day 154 and stay elevated through 
the termination of the study.
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